Ocular oncology


OXU-003 is a potential first-in-class registered treatment for retinoblastoma. OXU-003 is an innovative stable, sustained-release preparation of a proprietary chemotherapy agent. It is designed to be safely delivered in the suprachoroidal space, adjacent to primary retinoblastoma tumors using Oxulumis microcatheter. Once delivered, OXU-003 is designed to release the anti-cancer drug over prescribed treatment cycles. The …

OXU-003 Read More »

Scroll to Top